• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Worldwide evaluation of Clinical Practice Strategies (CliPS) for lung involvement in Still's disease within the JIR-CliPS network: a COST action.

作者信息

Jouret Maurine, Aguiar Francisca, Girard-Guyonvarc'h Charlotte, Vyzhga Yulia, Oliveira-Ramos Filipa, Lana Cristina Costa, Guedri Rahma, Lefevre-Utile Alain, Hadef Djohra, Angarita Juan Manuel Mosquera, Ozen Seza, Sahin Sezgin, Hashad Soad, Daghor-Abbaci Karima, Foell Dirk, Georgin-Lavialle Sophie, Theodoropoulou Katerina

机构信息

Pediatric Nephrology, Rheumatology, Dermatology Unit, Hospices Civils de Lyon, Lyon, France.

Adult and Pediatric Rheumatology Unit, ULS São JoãoYoung, Porto, Portugal.

出版信息

Rheumatol Adv Pract. 2025 Jul 3;9(3):rkaf073. doi: 10.1093/rap/rkaf073. eCollection 2025.

DOI:10.1093/rap/rkaf073
PMID:40901639
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12401577/
Abstract
摘要

相似文献

1
Worldwide evaluation of Clinical Practice Strategies (CliPS) for lung involvement in Still's disease within the JIR-CliPS network: a COST action.JIR-CliPS网络内关于斯蒂尔病肺部受累的临床实践策略（CliPS）的全球评估：一项欧洲科学与技术合作组织（COST）行动
Rheumatol Adv Pract. 2025 Jul 3;9(3):rkaf073. doi: 10.1093/rap/rkaf073. eCollection 2025.
2
Efficacy and safety of therapies for Still's disease and macrophage activation syndrome (MAS): a systematic review informing the EULAR/PReS guidelines for the management of Still's disease.Still 病和巨噬细胞活化综合征（MAS）治疗的疗效和安全性：一项系统评价，为 EULAR/PReS Still 病管理指南提供信息。
Ann Rheum Dis. 2024 Nov 14;83(12):1731-1747. doi: 10.1136/ard-2024-225854.
3
Efficacy and safety of biologic drugs in Still's disease: a systematic review and network meta-analysis of randomized controlled trials.生物制剂治疗斯蒂尔病的疗效与安全性：一项随机对照试验的系统评价和网状Meta分析
Rheumatology (Oxford). 2025 Jan 1;64(1):22-31. doi: 10.1093/rheumatology/keae295.
4
Advancing Point-of-Care Still's Murmur Identification: Evaluating the Efficacy of ConvNets and Transformers Using the StethAid Multicenter Heart Sound Database.推进即时护理期卡氏杂音识别：使用StethAid多中心心音数据库评估卷积神经网络和变换器的有效性。
IEEE Trans Biomed Eng. 2025 Sep 4;PP. doi: 10.1109/TBME.2025.3606341.
5
Managing the clinical heterogeneity of patients with Still's disease, from early diagnosis to timely treatment.应对斯蒂尔病患者的临床异质性，从早期诊断到及时治疗。
Autoimmun Rev. 2025 Jul 18;24(10):103880. doi: 10.1016/j.autrev.2025.103880.
6
Evaluation of clinical biomarkers for differential diagnosis of intravascular lymphoma and Still's disease.用于血管内淋巴瘤和斯蒂尔病鉴别诊断的临床生物标志物评估
Sci Rep. 2025 Jul 4;15(1):23901. doi: 10.1038/s41598-025-09401-4.
7
Coincident Kikuchi-Fujimoto's disease and adult-onset Still's disease: report of a patient from an uncommonly affected population and case-directed systematic review.同时发生的菊池古川病和成人Still 病：来自罕见发病人群的患者报告和病例导向的系统综述。
Clin Rheumatol. 2021 Dec;40(12):4791-4805. doi: 10.1007/s10067-021-05769-6. Epub 2021 Jun 7.
8
Current evidence on switching between biologic therapies for Still's disease: A systematic literature review.关于斯蒂尔病生物治疗转换的当前证据：一项系统文献综述。
Semin Arthritis Rheum. 2025 Oct;74:152789. doi: 10.1016/j.semarthrit.2025.152789. Epub 2025 Jul 18.
9
mTORC1 links pathology in experimental models of Still's disease and macrophage activation syndrome.mTORC1 将斯蒂尔病和巨噬细胞活化综合征的实验模型中的病理学联系起来。
Nat Commun. 2022 Nov 28;13(1):6915. doi: 10.1038/s41467-022-34480-6.
10
Bridging the gap between 2024 EULAR/PreS Recommendations for Still's Disease and practice: the need for awareness of biomarkers and timely use of IL-1/ IL-6 inhibition.弥合2024年欧洲抗风湿病联盟/Still病预治疗建议与临床实践之间的差距：认识生物标志物及及时使用白细胞介素-1/白细胞介素-6抑制剂的必要性。
ARP Rheumatol. 2025 Apr-Jun;4(2):177-178.

本文引用的文献

1
The clinical assessment of lung involvement in patients with Still's disease, results from the multicentre international AIDA Network Still's Disease Registry.斯蒂尔病患者肺部受累情况的临床评估，来自多中心国际AIDA网络斯蒂尔病登记处的结果。
Rheumatology (Oxford). 2025 Jan 20. doi: 10.1093/rheumatology/keaf021.
2
EULAR/PReS recommendations for the diagnosis and management of Still's disease, comprising systemic juvenile idiopathic arthritis and adult-onset Still's disease.EULAR/PReS 关于斯蒂尔病（包括全身型幼年特发性关节炎和成人斯蒂尔病）的诊断和治疗建议。
Ann Rheum Dis. 2024 Nov 14;83(12):1614-1627. doi: 10.1136/ard-2024-225851.
3
Recombinant Interleukin-1 Receptor Antagonist Is an Effective First-Line Treatment Strategy in New-Onset Systemic Juvenile Idiopathic Arthritis, Irrespective of HLA-DRB1 Background and IL1RN Variants.重组白细胞介素-1 受体拮抗剂是新诊断的全身型幼年特发性关节炎的有效一线治疗策略，与 HLA-DRB1 背景和 IL1RN 变异无关。
Arthritis Rheumatol. 2024 Jan;76(1):119-129. doi: 10.1002/art.42656. Epub 2023 Nov 6.
4
Lung Involvement in Systemic Juvenile Idiopathic Arthritis: A Narrative Review.全身型幼年特发性关节炎的肺部受累：一篇叙述性综述。
Diagnostics (Basel). 2022 Dec 8;12(12):3095. doi: 10.3390/diagnostics12123095.
5
Rare, rarer, lung involvement in adult-onset Still's disease: A mini-review.成人斯蒂尔病中罕见、更为罕见的肺部受累：一篇综述。
Front Med (Lausanne). 2022 Sep 16;9:989777. doi: 10.3389/fmed.2022.989777. eCollection 2022.
6
Parenchymal lung disease in adult onset Still's disease: an emergent marker of disease severity-characterisation and predictive factors from Gruppo Italiano di Ricerca in Reumatologia Clinica e Sperimentale (GIRRCS) cohort of patients.成人斯蒂尔病中的肺实质疾病：疾病严重程度的一个新出现的标志物——来自意大利临床与实验风湿病研究小组（GIRRCS）患者队列的特征及预测因素
Arthritis Res Ther. 2020 Jun 22;22(1):151. doi: 10.1186/s13075-020-02245-5.
7
Systemic Juvenile Idiopathic Arthritis-Associated Lung Disease: Characterization and Risk Factors.系统性幼年特发性关节炎相关肺病：特征和危险因素。
Arthritis Rheumatol. 2019 Nov;71(11):1943-1954. doi: 10.1002/art.41073. Epub 2019 Oct 1.
8
Pulmonary hypertension and other potentially fatal pulmonary complications in systemic juvenile idiopathic arthritis.系统性幼年特发性关节炎中的肺动脉高压和其他潜在致命性肺部并发症。
Arthritis Care Res (Hoboken). 2013 May;65(5):745-52. doi: 10.1002/acr.21889.